BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) CEO James Passen tells Proactive it has partnered with Ohio State University to further develop the company’s haptenized viral antigen platform to create a broadly reactive pan-sarbecovirus vaccine. The Vancouver-based company said this is its second research collaboration in the SARS-CoV-2 field with Ohio State. Sarbecoviruses, a subset of the coronaviridae family, include the emerging SARS2 variants Delta and Omicron. Sarbecoviruses are responsible for two pandemics in less than 20 years including SARS-CoV-1 (SARS1) in 2003 and the current coronavirus pandemic.
BioVaxys forms 2nd collaboration with Ohio State University for research on pan-sarbecovirus vaccine
